← Shelf·GIP + GLP-1 + glucagon triple agonist·III.
Retatrutide.
A synthetic 39-amino-acid peptide (also known as LY3437943) that binds three receptors: GIP, GLP-1, and glucagon. Investigational Eli Lilly compound; not FDA-approved as of writing.
GIP, GLP-1, and glucagon each engage their own receptor and each drive their own downstream tissue effects — normally as three independent signals. Retatrutide's design is to engage all three receptors with a single molecule.
The 'next-generation GLP' story is the most breathless corner of the internet in this category. Distinguishing what the published Phase-II data actually says from what the takes-per-second machine says about it is a twenty-minute read in the primary sources. That is what we are pointing you to.
Straight talk
Straight talk: retatrutide is investigational. Not FDA-approved. The Phase-II data is published; the Phase-III data is being generated. Whether the research-grade compound in a given vial IS the same molecule as Lilly's clinical-trial candidate is exactly what a third-party COA is for. Buy on documentation, not on adjacency to a headline compound.
What the research studies
The literature, not a summary of it.
The Phase-I and Phase-II record centers on Rosenstock and Coskun's teams at Lilly, published in NEJM and Lancet. Trial registrations are on ClinicalTrials.gov. Read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025). Sold by Amino Club as GLP-3 (RT); the coded product name is the vendor's, the INN is ours for reference.
From $45.49 during Fall Sale (was $69.99, 10MG)
35% off applied automatically at checkout when you land through this link.
Related on the shelf